ScoreWhy is Kilitch Drugs (India) Ltd ?
1
Poor Management Efficiency with a low ROE of 8.85%
- The company has been able to generate a Return on Equity (avg) of 8.85% signifying low profitability per unit of shareholders funds
2
Company has a Debt to Equity ratio (avg) of 0.01 times
3
Healthy long term growth as Operating profit has grown by an annual rate 59.44%
- PBT LESS OI(Q) At Rs 19.72 cr has Grown at 297.6% (vs previous 4Q average)
- OPERATING PROFIT TO INTEREST(Q) Highest at 15.38 times
- NET SALES(Q) Highest at Rs 89.60 cr
4
With ROE of 10.8, it has a Fair valuation with a 2.4 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -17.44%, its profits have risen by 14.6% ; the PEG ratio of the company is 4
5
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Kilitch Drugs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Kilitch Drugs for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Kilitch Drugs
-17.44%
-0.37
47.02%
Sensex
-10.34%
-0.79
13.08%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
28.00%
EBIT Growth (5y)
59.44%
EBIT to Interest (avg)
4.88
Debt to EBITDA (avg)
1.79
Net Debt to Equity (avg)
0.07
Sales to Capital Employed (avg)
0.72
Tax Ratio
23.69%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
10.97%
ROE (avg)
8.85%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
22
Industry P/E
33
Price to Book Value
2.36
EV to EBIT
20.60
EV to EBITDA
18.57
EV to Capital Employed
2.27
EV to Sales
2.89
PEG Ratio
4.00
Dividend Yield
NA
ROCE (Latest)
11.00%
ROE (Latest)
10.79%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
PBT LESS OI(Q)
At Rs 19.72 cr has Grown at 297.6% (vs previous 4Q average
OPERATING PROFIT TO INTEREST(Q)
Highest at 15.38 times
NET SALES(Q)
Highest at Rs 89.60 cr
PBDIT(Q)
Highest at Rs 22.14 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 24.71%
PAT(Q)
Highest at Rs 14.52 cr.
-2What is not working for the Company
INTEREST(Q)
At Rs 1.44 cr has Grown at 25.22%
Loading Valuation Snapshot...
Here's what is working for Kilitch Drugs
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 19.72 cr has Grown at 297.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 4.96 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 14.52 cr has Grown at 123.0% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 6.51 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
At Rs 89.60 cr has Grown at 73.1% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 51.78 CrMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Operating Profit to Interest - Quarterly
Highest at 15.38 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Sales - Quarterly
Highest at Rs 89.60 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 22.14 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 24.71%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 19.72 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 14.52 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Here's what is not working for Kilitch Drugs
Interest - Quarterly
At Rs 1.44 cr has Grown at 25.22%
Quarter on Quarter (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
